










                     
                
                 
                    
                 
             
              
           
             
           
             
            
             
                 
               
                
             
                 
               
              
        
 
 
               
                
                     
                  
             
                   
                    
                 
                 
                    
             
                   
               
                
                   
              













                 
                   
             
              
                   
                    
               
                 
                 
 
 
              
                 
              
       
 
                
               
                    
               
               
   
 
            
           
              
             
             
         
                 
         
 
                    
                 
               
 
                    
                  
               
           
 
                
           
             
             
             
Florida State‐based 
Amyotrophic Lateral Sclerosis (ALS) 
Surveillance Project Summary 
BACKGROUND 
ALS, or Lou Gehrig’s disease, is a rare, difficult to diagnose 
neurological condition with no known cause or cure. 
Because ALS is a non‐notifiable disease, little is known 
about its incidence and prevalence in the U.S. To help 
learn more about ALS, the federal Agency for Toxic 
Substances and Disease Registry (ATSDR) maintains the 
National ALS Registry (Registry).1,2 The Registry identifies 
ALS cases using national administrative databases, 
including those from Medicaid, Medicare, and the 
Veterans Health Administration and Veterans Benefits 
Administration, and by patient self‐enrollment through a 
web portal. ATSDR funded McKing Consulting 
Corporation (McKing) to complete surveillance projects to 
gather reliable and timely data to describe the incidence 
and demographic characteristics of ALS and to assist 
ATSDR in evaluating the completeness of the Registry. 
Surveillance projects were conducted in three states 
(Florida, New Jersey, and Texas) and in eight metropolitan 
areas (Atlanta, Baltimore, Chicago, Detroit, Las Vegas, Los 
Angeles, Philadelphia, and San Francisco). This summary 
describes the Florida project. 
METHODS 
McKing partnered with the Florida Department of Health 
(FLDOH) to conduct the project. All neurologists practicing 
in the state of Florida were asked if they diagnosed or 
provided care for ALS patients. Emphasis was placed on 
neurologists specializing in the diagnosis/care of persons 
with ALS who practice at referral centers that typically see 
more than 50 patients per year. Neurologists were asked to 
submit one‐page case reports for ALS patients under the 
doctor’s care who were alive at some point between 
January 1, 2009 and December 31, 2011. A medical record 
verification form (MRVF) and an electromyogram (EMG) 
report were requested for a sample of cases and reviewed 
by an independent consulting neurologist to confirm ALS 
diagnosis. Death data were reviewed to identify additional 
cases, and attempts were made to obtain case reports for 
decedents that were not already reported. Compensation 
was offered to neurologists for completed forms. No 
patients were contacted. 
Crude incidence rates were calculated using the count of 
cases diagnosed in each year as the numerator and the 
corresponding U.S. Census population data3 as the 
denominator. Crude average annual incidence rates were 
calculated by adding the incidence rates for the three years 
and then dividing by three. This project was approved by 
the Centers for Disease Control and Prevention Institutional 
Review Board (IRB) and determined to be public health 
practice not requiring review by the FLDOH IRB. 
RESULTS 
►	 Thirty percent (258/862) of neurologists indicated that 
they diagnosed and/or cared for ALS patients and 57% 
(148/258) of those neurologists reported cases. All 
major referral centers participated. 
►	 Using 2010 U.S. Census population data and estimates 
of incidence and prevalence, we expected to identify 
1,500 unique cases in the project area.3,4 A total of 
1,843 case reports were received; 1,451 were unique 
cases, which is approximately 97% (1,451/1,500) of the 
expected cases. 
►	 Seventy‐nine percent (1,148/1,451) of cases were 
reported as “definite,” “probable,” or “probable‐lab 
supported” according to the El Escorial criteria.5 
Seventy percent (188/269) of the requested MRVFs 
were received; 79% (149/188) were classified as 
“definite,” “probable,” or “probable‐lab supported,” 
and 21% (39/188) were classified as “possible” or “not 
classifiable” by the consulting neurologist. 
►	 Eighty‐four percent of cases were 50 years of age or 
older at diagnosis, 58% were male, 73% were white, 
and 75% were not Hispanic or Latino (Table). 
►	 Of the 1,194 cases for whom data were available, 50% 
had symptoms for 11 months or less before diagnosis. 
Ninety percent of the 1,194 cases were diagnosed 
within 36 months of having symptoms. 
►	 Forty percent (576/1,451) of cases had only federal 
payers [Medicare, Medicaid, Veterans Affairs (VA)], 
36% (524/1,451) had only non‐federal payers (HMO, 
private insurance, self‐pay, or other), and 24% 
(351/1,451) had both federal and non‐federal payers. 
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► There were 1,022 cases diagnosed in 2009‐2011. The DISCUSSION 
crude incidence rates for 2009, 2010, and 2011 
ranged from 1.71 to 1.93 cases per 100,000 person‐
years. The crude average annual incidence rates 
between males and females and between whites and 
Blacks/African Americans were significantly different 
(Figure). The age‐adjusted average annual incidence 
rate for the three‐year period was 1.43 cases per 
100,000 person‐years. 
Table: Demographic Characteristics of All Reported ALS Cases in 
Florida, n=1,451 
Demographic Characteristic n %* 
Age (years) 
Under 40 80 5.5 
40 – 49 161 11.1 
50 – 59 309 21.3 
60 – 69 451 31.1 
70 – 79 337 23.2 
80 or older 104 7.2 
Unknown 9 0.6 
Sex 
Male 839 57.8 
Female 612 42.2 
Race 
White alone 1058 73.0 
Black/African American alone 89 6.1 
Asian alone 17 1.2 
Other** 5 0.3 
Unknown 282 19.4 
Ethnicity 
Hispanic 156 10.8 
Not Hispanic or Latino 1085 74.7 
Unknown 210 14.5 
*May not add up to 100% due to rounding. 
**Those with multiple races are listed here. 
Figure: Stratified Crude Average Annual Incidence Rates for ALS 
























Sex Race All 
The shaded bars represent the subgroup rates. 
Incidence rates are per 100,000 person‐years. 
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►	 Thirty percent of neurologists diagnosed or cared for 
patients with ALS during the reporting period and 
more than one‐half of them reported cases. 
►	 All ALS referral centers in the region participated and 
submitted the majority of case reports. 
►	 Some non‐referral center practices in the region and 
one VA hospital participated. The remaining VA 
hospitals and clinics and some non‐referral center 
practices declined to participate. However, it is 
unclear if providers at these practices would have 
reported unique ALS cases. 
►	 Many unique names were identified in the death 
data that were not reported to the project. It is 
unknown if any of these individuals were true ALS 
cases. 
►	 We found higher crude annual incidence rates 
among ALS cases that were older, male, and white, 
which is consistent with published literature.4,6,7 The 
difference in crude rates between males and females 
and between whites and Blacks/African Americans 
was statistically significantly different. 
►	 Examining localized ALS incidence and demographics 
may help to reveal at‐risk populations for further 
studies. 
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